European Institute of Oncology

Early diagnosis, either through blood tests looking for tumour biomarkers, or through wider use of scanning technology such as mammograms, will also help us tailor treatment more specifically to the patient, that goal of precision oncology that we heard about at the beginning of this podcast.

Giuseppe Curigliano is professor of medical oncology at the University of Milan in Italy and director of the early drug development division at the European Institute of Oncology based in the city.

He's also the president-elect of ESMO, the European Society of Medical Oncology.

Biomarkers are really important in the navigation system of modern oncology.

Okay.

And as a follow-up to that, the next question from Eleonora Panizzolo from the European Institute of Oncology, she's asking, if not re-injecting, are there any other particular technical modifications that you suggest in order for us to optimize bilateral detections?

So I think the most important thing that we learned was that basic surgical principles remain the same, but the operation becomes progressively more technically demanding as the uterus enlarges.

But this is not unique to the sentinel lymph node.

This is medical oncologist Dr. Neil Love.

At the 2026 Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Westin from the MD Anderson Cancer Center in Houston and faculty members Professor Nicoletta Colombo, from the European Institute of Oncology, IRCCS, in Milan, Italy, Dr. Alexander Olawaiya from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Gottfried Konechny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of pre-recorded video case presentations by Professor Jonathan Letterman from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Matalonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient from Professor Letterman, a 70-year-old woman with a previous history in 2016 of surgery for stage 3 endometrioid high-grade carcinoma of the ovary.

This is medical oncologist Dr. Neil Love.

At the 2026 Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Weston from the MD Anderson Cancer Center in Houston and faculty members Professor Nicoletta Colombo, from the European Institute of Oncology, IRCCS, in Milan, Italy, Dr. Alexander Olawaiye from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Gottfried Konechny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of pre-recorded video case presentations by Professor Jonathan Letterman from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Matalonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient of Dr. Secord, a 69-year-old woman with a germline BRCA2 mutation who was status post multiple surgeries, intraperitoneal chemotherapy, but with further progression of platinum-resistant disease.